HOXA9 and ovarian carcinoma: The combined panel of HOXA9 + HIC1 showed the best discriminatory efficiencies at all stages of ovarian cancer (80.0% (16/20) of stage I/II, 90.7% (49/54) of stage III, and 90.9% (10/11) of stage IV of ovarian cancer).